Episode #48: New Biosimilars Available to Treat IBD (what it means for your patients)

This summer, four new biosimilar drugs became available to U.S. patients and several more are expected to hit the market soon.

Dr. Michael Weinstein interviews Laura D. Wingate, executive vice president, education, support, & advocacy for the Crohn’s & Colitis Foundation about the positive and negative implications of this development for patients.

Continue reading “Episode #48: New Biosimilars Available to Treat IBD (what it means for your patients)”

Episode #21: Educating and Advocating on Behalf of IBD Patients and Caregivers (diversity and inclusion are mission critical)

This week, Kevin Harlen talks with Michael Osso, president and CEO of the Crohn’s & Colitis Foundation about its mission to cure inflammatory bowel disease (IBD) and to improve the quality of life for children and adults affected by these diseases.

Continue reading “Episode #21: Educating and Advocating on Behalf of IBD Patients and Caregivers (diversity and inclusion are mission critical)”